Type | Public | |
Founded | 2000 | |
HQ | Brentford, GB | Map |
Website | gsk.com | |
Employee Ratings | ||
Overall Culture | A | More |
GSK has offices in Brentford, Philadelphia, Boumerdes, San Fernando and in 88 other locations
GSK's revenue was reported to be £34.11 b in FY, 2021
GBP
Revenue (Q2, 2022) | £9.45 b |
Gross profit (Q2, 2022) | £8.53 b |
Gross profit margin (Q2, 2022), % | 90.2% |
Net income (Q2, 2022) | £975 m |
EBITDA (Q2, 2022) | £6.32 b |
EBIT (Q2, 2022) | £1.42 b |
Market capitalization (01-Aug-2022) | £68.89 b |
Closing stock price(01-Aug-2022) | £16.94 |
Cash (30-Jun-2022) | £6.47 b |
EV | $84.54 b |
GSK's current market capitalization is £68.9 b.
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 7.7 b | 7.8 b | 9.4 b | 9.1 b | 7.6 b | 8.6 b | 7.4 b | 8.1 b | 9.1 b | 9.8 b | 9.5 b |
Cost of goods sold | 2.7 b | 2.6 b | 3.2 b | 3.2 b | 2.4 b | 2.9 b | 2.5 b | 2.6 b | 2.9 b | 3.7 b | (572 m) |
Gross profit | 4.9 b | 5.2 b | 6.1 b | 5.9 b | 5.2 b | 5.8 b | 4.9 b | 5.5 b | 6.2 b | 6.1 b | 8.5 b |
Gross profit Margin, % | 64% | 66% | 65% | 65% | 68% | 67% | 67% | 68% | 68% | 62% | 90% |
GBP | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 4.1 b | 4.1 b | 4.3 b | 4.8 b | 8.2 b | 4.3 b | 4.8 b | 3.5 b | 3.5 b | 11 b | 6.5 b |
Accounts Receivable | 6.6 b | 6.9 b | 8.2 b | 8.5 b | 7.2 b | 7.9 b | 6.5 b | 6.9 b | 7.7 b | 8.3 b | 6.5 b |
Prepaid Expenses | 413 m | ||||||||||
Inventories | 5.7 b | 6 b | 6.8 b | 6 b | 6.4 b | 6.4 b | 6.2 b | 6.3 b | 6.2 b | 6 b | 4.7 b |
EV/EBITDA | 16.7 x |
EV/EBIT | 74.5 x |
EV/CFO | 25.2 x |
Debt/Equity | 1.0 x |
Debt/Assets | 0.2 x |
Financial Leverage | 3.9 x |
GSK revenue breakdown by business segment: 28.2% from Consumer Healthcare, 52.0% from Global Pharmaceuticals and 19.9% from Vaccines
GSK revenue breakdown by geographic segment: 23.0% from Europe, 32.8% from International and 44.2% from US
GSK's Vaccines was reported to be 767 m in FY, 2021.
Company Name | Date | Deal Size |
---|---|---|
Sierra Oncology | April 13, 2022 | $1.9 b |
Pfizer Biotech Corporation Taiwan | September 28, 2020 | £129 m |
Sitari Pharmaceuticals | September 12, 2019 | |
TESARO | December 04, 2018 | $5.1 b |
GlycoVaxyn | February 11, 2015 | $190 m |
Okairos AG | May 29, 2013 | $325 m |
Human Genome Sciences | August 03, 2012 | $3 b |
CellZome | May 15, 2012 | £61 m |
MaxiNutrition | December 13, 2010 | £162 m |
Nanjing MeiRui Pharma Co., Ltd. | December 07, 2010 | $70 m |
Source: uploads5.craft.co, www.gsk.com, uploads4.craft.co
Source: 9 public H-1B filings from GSK
13.31 k
Tweets
719
Following
238.7 k
Followers
42
Tweets last 30 days
17.3
Avg. likes per Tweet
81%
Tweets with engagement
27 products used
46 products used
15 products used
3 products used
A
77/100
A+
80/100
A-
76/100
B+
75/100
Receive alerts for 300+ data fields across thousands of companies